| Michael Philip Hood, MD | |
|
1851 S Kelly Ave Ste A, Edmond, OK 73013-3929 | |
| (405) 607-6699 | |
| Not Available |
| Full Name | Michael Philip Hood |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 13 Years |
| Location | 1851 S Kelly Ave Ste A, Edmond, Oklahoma |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386932333 | NPI | - | NPPES |
| 200814060A | Medicaid | OK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207WX0107X | Ophthalmology - Retina Specialist | 52493 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Summit Medical Center | Edmond, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Retina Vitreous Center, Pllc | 3375712763 | 5 |
News Archive
Auxogyn, Inc., a company dedicated to advancing women's reproductive health, today announced an exclusive license agreement with Merck Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany which operates as EMD Serono in the United States and Canada, for Auxogyn's proprietary Early Embryo Viability Assessment (Eeva) Test.
Mylan N.V. today announced that its abbreviated new drug application (ANDA) for fluticasone propionate 100, 250, 500 mcg and salmeterol 50 mcg inhalation powder has been accepted for filing by the U.S. Food and Drug Administration.
A research project at the University of Illinois is examining the use of mindfulness therapy in preventing drug abuse relapse among marginalized young adults.
Selexis SA, a global life science company with technologies for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins announced today that CSL Limited has entered a commercial license agreement with Selexis for the preclinical development of a therapeutic antibody anticipated to enter Phase I clinical trials in 2012.
› Verified 5 days ago
| Entity Name | Retina Vitreous Center, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811284946 PECOS PAC ID: 3375712763 Enrollment ID: O20110801000342 |
News Archive
Auxogyn, Inc., a company dedicated to advancing women's reproductive health, today announced an exclusive license agreement with Merck Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany which operates as EMD Serono in the United States and Canada, for Auxogyn's proprietary Early Embryo Viability Assessment (Eeva) Test.
Mylan N.V. today announced that its abbreviated new drug application (ANDA) for fluticasone propionate 100, 250, 500 mcg and salmeterol 50 mcg inhalation powder has been accepted for filing by the U.S. Food and Drug Administration.
A research project at the University of Illinois is examining the use of mindfulness therapy in preventing drug abuse relapse among marginalized young adults.
Selexis SA, a global life science company with technologies for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins announced today that CSL Limited has entered a commercial license agreement with Selexis for the preclinical development of a therapeutic antibody anticipated to enter Phase I clinical trials in 2012.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael Philip Hood, MD Po Box 2492, Edmond, OK 73083-2492 Ph: (405) 607-6699 | Michael Philip Hood, MD 1851 S Kelly Ave Ste A, Edmond, OK 73013-3929 Ph: (405) 607-6699 |
News Archive
Auxogyn, Inc., a company dedicated to advancing women's reproductive health, today announced an exclusive license agreement with Merck Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany which operates as EMD Serono in the United States and Canada, for Auxogyn's proprietary Early Embryo Viability Assessment (Eeva) Test.
Mylan N.V. today announced that its abbreviated new drug application (ANDA) for fluticasone propionate 100, 250, 500 mcg and salmeterol 50 mcg inhalation powder has been accepted for filing by the U.S. Food and Drug Administration.
A research project at the University of Illinois is examining the use of mindfulness therapy in preventing drug abuse relapse among marginalized young adults.
Selexis SA, a global life science company with technologies for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins announced today that CSL Limited has entered a commercial license agreement with Selexis for the preclinical development of a therapeutic antibody anticipated to enter Phase I clinical trials in 2012.
› Verified 5 days ago
Bradley Don Britton, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 14701 N Santa Fe Ave, Edmond, OK 73013 Phone: 405-752-2733 Fax: 405-752-2172 | |
Mrs. Laura Sarfatis Miles, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 912 Nw 139th Street Pkwy, Edmond, OK 73013 Phone: 405-608-4447 Fax: 405-286-1261 | |
Jeffrey T Shaver, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3840 South Boulevard, Suite 101, Edmond, OK 73013 Phone: 405-471-5252 Fax: 405-726-8530 | |
Brian Dale Morgan, M.D. Ophthalmology Medicare: May Accept Medicare Assignments Practice Location: 14701 N Santa Fe Ave, Edmond, OK 73013 Phone: 405-752-2733 Fax: 405-752-2172 | |
Robert D Gourley, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 920 S Bryant Ave, Ste 100, Edmond, OK 73034 Phone: 405-341-4238 Fax: 405-340-0269 | |
Dr. Thomas C Wolf, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3431 S Boulevard St, Suite 106, Edmond, OK 73013 Phone: 405-562-2036 Fax: 405-562-2116 | |
Dr. Sandeep N Shah, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1851 S Kelly Ave Ste A, Edmond, OK 73013 Phone: 405-607-6699 Fax: 405-607-6685 |